Major depressive order affects over 300 million people worldwide, growing 37% each decade. Patients do not usually receive adequate care due to its heterogeneity, which affects each individual with highly different treatment responses. This situation involves social issues and increasing economic costs, reaching up to €170 billion per year to the EU.
To adapt each treatment and ensure patients’ better quality of life, Genetika+ has created RxMine, a precision medicine solution for depression. Using a simple blood test and machine learning algorithms, RxMine can screen dozens of drug scenarios and combinations in vitro to study the most suitable option for each patient’s responsiveness.
With proper treatment, Genetika+ stands for improving depression worldwide: reducing patients’ suffering and improving their daily life.
